Skip to main content
Log in

Opinion statement

  • Physicians must aggressively treat heart failure in the early stages to prevent disease progression and improve survival. Early treatment implies early diagnosis of left ventricular (LV) dysfunction, before the onset of symptoms. Patients with risk factors for the development of heart failure, especially coronary disease or hypertension, should undergo echocardiography to evaluate LV function. Patients with LV systolic dysfunction should be further evaluated to determine the type of cardiac dysfunction, uncover correctable etiologic factors, determine prognosis, and guide treatment.

  • Angiotensin-converting enzyme (ACE) inhibitors and beta-adrenergic blocking drugs improve survival and are integral to the treatment plan. Physicians should prescribe an ACE inhibitor as initial therapy for all patients with LV systolic dysfunction unless there are specific contraindications. The combination of hydralazine and isosorbide dinitrate is an acceptable alternative therapy for patients who cannot take ACE inhibitors.

  • Diuretics should be used if there are signs or symptoms of volume overload.

  • Beta-adrenergic blocking drugs should be added to therapy in stable patients with mild to moderate heart failure after optimal treatment with ACE inhibitors, diuretics, or other vasodilators.

  • Digoxin should be used routinely in patients with severe heart failure and should be added to therapy in patients with mild to moderate heart failure who remain symptomatic despite optimal doses of ACE inhibitors and diuretics.

  • Spironolactone should be added, but electrolytes should be closely monitored.

  • Warfarin anticoagulation should be considered in patients with a left ventricular ejection fraction (LVEF) of 35% or less.

  • Until survival data exist, angiotensin receptor blockers (ARBs) should not be used as initial therapy or as sole therapy but can be used for ACE-intolerant patients or can be added to standard heart failure therapy.

  • Outpatient use of intravenous inotropic therapy should be avoided.

  • Patients with severe heart failure should have peak oxygen consumption measured to quantify functional impairment, determine prognosis, and identify the need for advanced heart failure therapy.

  • Patients who remain symptomatic while receiving optimal standard therapy should be referred early to a specialized heart failure center.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Konstam M, Dracup K, Baker S, et al.: Heart Failure: Evaluation and Care of Patients with Left Ventricular Systolic Dysfunction. Clinical Practice Guidelines No.11. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services; 1994. [AHCPR Publication No. 94-0612.]

    Google Scholar 

  2. American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Guidelines for the evaluation and management of heart failure. Circulation 1995, 92:2764–2784.

    Google Scholar 

  3. Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure: Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999, 83:1A-38A. The most up-to-date guidelines for the management of heart failure, incorporating beta-blockers in the management plan.

    Article  Google Scholar 

  4. Garg R, Yusef S, for the Collaborative Group on ACE Inhibitor Trials: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995, 273:1450–1456. A meta-analysis of the major survival trials of angiotensinconverting enzyme inhibitors in heart failure.

    Article  PubMed  CAS  Google Scholar 

  5. Alderman EL: Results from late-breaking clinical trials sessions at ACC 98. J Am Coll Cardiol 1998, 32:1–7.

    Article  PubMed  CAS  Google Scholar 

  6. Heidenreich PA, Lee TT, Massie BM: Effect of beta blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997, 30:27–34. A meta-analysis of the major beta-blocker survival trials in patients with heart failure.

    Article  PubMed  CAS  Google Scholar 

  7. CIBIS II Investigators and Committees: The cardiac insufficiency bisoprolol study II (CIBIS II): a randomized trial. Lancet 1999, 353:9–13.

    Article  Google Scholar 

  8. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001–2007.

    Article  Google Scholar 

  9. The BEST Steering Committee: Design of the Beta- Blocker Survival Trial (BEST). Am J Cardiol 1995, 75:1220–1223.

    Article  Google Scholar 

  10. The Digitalis Intervention Group: The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525–533.

    Article  Google Scholar 

  11. Packer M, Gheorghiade M, Young JB, et al.: Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors: RADIANCE study. N Engl J Med 1993, 329:1–7.

    Article  PubMed  CAS  Google Scholar 

  12. Uretsky BF, Young JB, Shahidi FE, et al. on behalf of the PROVED Investigative Group: Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993, 22:955–962.

    Article  PubMed  CAS  Google Scholar 

  13. Eichhorn E: Talk presented at the American Heart Association Scientific Session. Dallas: American Heart Association Scientific Session; 1998.

    Google Scholar 

  14. Pitt B, Zannad F, Remme WF, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, in press.

  15. Cohn JN, Archibald DG, Ziesche A, et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Cooperative Study. N Engl J Med 1986, 314:1547–1552.

    Article  PubMed  CAS  Google Scholar 

  16. Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure (V-HeFT II). N Engl J Med 1991, 325:303–310.

    Article  PubMed  CAS  Google Scholar 

  17. Yusef S, Maggioni AP, Held P, et al.: Effects of candesartan, enalapril or their combination on exercise capacity, ventricular function, clinical deterioration and quality of life in heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) [abstract]. Circulation 1997, 96(suppl):452.

    Google Scholar 

  18. Pitt B, Segal R, Martinez F, et al.: Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997, 349:747–752.

    Article  PubMed  CAS  Google Scholar 

  19. Al-Khadra AS, Salem DN, Rand WM, et al.: Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998, 31:749–753.

    Article  PubMed  CAS  Google Scholar 

  20. Pfeffer MA, Braunwald E, Moye LA, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Result of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992, 327:669–677.

    Article  PubMed  CAS  Google Scholar 

  21. Packer M, O’Connor CM, Ghali JK, et al. for the Prospective Randomized Amlodipine Survival Evaluation Study Group: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996, 335:1107–1114.

    Article  PubMed  CAS  Google Scholar 

  22. Cohn JN, Ziesche S, Smith R, et al. for the Vasodilator- Heart Failure Trial (V-HeFT) Study Group: Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril. Circulation 1997, 96:856–863.

    PubMed  CAS  Google Scholar 

  23. Waldo AL, Camm AJ, DeRuyter H, et al. for the SWORD investigators: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996, 348:7–12.

    Article  PubMed  CAS  Google Scholar 

  24. Packer M, Carver JR, Rodeheffer RJ, et al. for the PROMISE Study Research Group: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991, 325:1468–1475.

    Article  PubMed  CAS  Google Scholar 

  25. Feldman AM, Bristow MR, Parmley WW, et al.: Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 1993, 329:149–155.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Winkel, E., Costanzo, M.R. Chronic heart failure. Curr Treat Options Cardio Med 1, 231–241 (1999). https://doi.org/10.1007/s11936-999-0039-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-999-0039-z

Keywords

Navigation